# Ocular Therapeutix, Inc. (OCUL)

> Ocular Therapeutix, Inc. (OCUL) trades at $5.57 (-4.95%) as of 7:30:05 PM EST on Nov 20, 2026, -15.73% over the past month. Market cap is $1.22B, with 10.1 days to cover in short interest.

Canonical: https://massive.com/quote/ocul
Data as of: 2026-11-21T00:30:05.443Z (15-minute delayed)
Source: Massive (https://massive.com/docs/llms.txt)

## Price

**$5.57** -0.29 (-4.95%)
At close · 15-minute delayed
Nasdaq · usd

After hours: **$5.60** +0.03 (+0.54%)
As of 7:30:05 PM EST on Nov 20, 2026 · After hours

## Stock performance

How Ocular Therapeutix, Inc. (OCUL) stock has performed from one day to one year, with its 52-week range.

| Period | Return |
| --- | --- |
| 1D | -4.95% |
| 1W | -10.31% |
| 1M | -15.73% |
| YTD | -54.12% |
| 1Y | -53.97% |
| 52-wk range | $5.54 – $16.44 |

From daily closes through Nov 20, 2026.

## Key statistics

Today's trading snapshot for OCUL: day range, open, previous close, volume and market cap.

| Measure | Value |
| --- | --- |
| Day range | $5.54 – $5.95 |
| Open | $5.76 |
| Prev close | $5.86 |
| Volume | 2.9M |
| Market cap | $1.22B |
| Shares out | 220.02M |

## Valuation and profitability ratios

Valuation and profitability ratios for Ocular Therapeutix, Inc.: P/E, P/S, P/B, ROE and more.

| Measure | Value |
| --- | --- |
| P/E | — |
| P/S | 24.31 |
| P/B | 2.78 |
| P/FCF | — |
| ROE | -74.1% |
| ROA | -54.0% |
| Debt/Equity | 0.17 |
| Div yield | 0.00% |

As of Nov 20, 2026

## Insider trading

[Ocular Therapeutix, Inc. (OCUL) insider trading](https://massive.com/quote/ocul/insider-trading.md): open-market Form 4 buys and sells by Ocular Therapeutix, Inc. insiders over the last 12 months.

## 8-K filings

Material corporate events Ocular Therapeutix, Inc. has disclosed to the SEC on Form 8-K.

- Nov 9, 2026 · Director departure
  “On November 6, 2026, Seung Suh Hong, Ph.D., notified the Company of his resignation from the Board, effective December 31, 2026. Dr. Hong's resignation is not the result of any disagreement with the Board or with management on any matter relating to the Company's operations, policies or practices.”
- Nov 9, 2026 · [Quarterly earnings](https://massive.com/quote/sec-filings/8-k/earnings-releases.md)
  “On November 9, 2026, Ocular Therapeutix, Inc. announced its financial results for the quarter ended September 30, 2026. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.”
- Oct 16, 2026 · [Executive officer departure](https://massive.com/quote/sec-filings/8-k/executive-departures.md)
  “On October 14, 2026, Sanjay Nayak, M.B.B.S., Ph.D., Chief Strategy Officer of Ocular Therapeutix, Inc. (the "Company"), notified the Company of his resignation from the Company, effective October 16, 2026, to become the Chief Executive Officer of a privately-held company.”
- Jun 12, 2026 · Executive compensation change
  “Additionally, the Company granted Mr. Robins, effective June 10, 2026 (the 'Grant Date'), (i) a stock option to purchase up to 14,024 shares of the Company's common stock at a per share exercise price equal to the closing price of the Company's common stock on The Nasdaq Global Market on the Grant Date and (ii) a restricted stock unit award representing the right to receive 15,441 shares of the Company's common stock. Subject to Mr. Robins' continued service to the Company, his option award vests in equal monthly installments over a four-year period, and his restricted stock unit award vests in equal yearly installments over a three-year period.”
- Feb 27, 2026 · Investor presentation
  “Ocular Therapeutix, Inc. (the "Company") will make available under the Investors section of its corporate website the slides to be presented by the Company at the 49th Macula Society Annual Meeting on February 27, 2026”

## OCUL short interest

How heavily OCUL is shorted: shares short, days to cover and average daily volume.

| Measure | Value |
| --- | --- |
| Days to cover | 10.1 |
| Short interest | 29M |
| Avg volume | 2.86M |

As of Oct 30, 2026 · reported to FINRA twice monthly.

## OCUL news

The latest news and headlines about Ocular Therapeutix, Inc. (OCUL).

- [Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)](https://www.globenewswire.com/news-release/2026/11/20/3407352/0/en/ocular-therapeutix-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4.html) · GlobeNewswire Inc. · Nov 20, 2026 · neutral sentiment
- [Ocular Therapeutix (OCUL) Reports Q3 Loss, Lags Revenue Estimates](https://www.zacks.com/stock/news/3026157/ocular-therapeutix-ocul-reports-q3-loss-lags-revenue-estimates?cid=CS-ZC-FT-fundamental_analysis|yseop_template_4-3026157) · Zacks Investment Research · Nov 9, 2026 · negative sentiment
- [Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)](https://www.globenewswire.com/news-release/2026/11/06/3397436/0/en/ocular-therapeutix-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4.html) · GlobeNewswire Inc. · Nov 6, 2026 · neutral sentiment
- [Corcept Therapeutics (CORT) Q3 Earnings and Revenues Surpass Estimates](https://www.zacks.com/stock/news/3022258/corcept-therapeutics-cort-q3-earnings-and-revenues-surpass-estimates?cid=CS-ZC-FT-fundamental_analysis|yseop_template_4-3022258) · Zacks Investment Research · Nov 3, 2026 · positive sentiment
- [Diabetic Retinopathy Pipeline Insight 2026: Comprehensive Analysis of 50+ Companies and 55+ Drugs in Development](https://www.globenewswire.com/news-release/2026/07/03/3321868/28124/en/Diabetic-Retinopathy-Pipeline-Insight-2026-Comprehensive-Analysis-of-50-Companies-and-55-Drugs-in-Development.html) · GlobeNewswire Inc. · Jul 3, 2026 · positive sentiment

## About Ocular Therapeutix, Inc.

Ocular Therapeutix Inc is a biotechnology company that specializes in therapies for diseases and conditions of the eye. The company uses its proprietary hydrogel platform technology to deliver therapeutic agents to the eye. Its pipeline consists of eye medication that aims to overcome the limitations of current eye-drop-based therapies for ophthalmic diseases and conditions. Its pipeline product includes Dextenza, OTX-TIC, OTX-TKI, and OTX-IVT.

| Measure | Value |
| --- | --- |
| Exchange | Nasdaq |
| Market | stocks |
| Type | CS |
| Currency | USD |
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 325 |
| Listed | Jul 25, 2014 |

[Company website](https://www.ocutx.com)

## FAQ

### What is the Ocular Therapeutix, Inc. (OCUL) stock price today?

Ocular Therapeutix, Inc. (OCUL) is trading at $5.57 (-4.95% on the day) as of 7:30:05 PM EST on Nov 20, 2026. Prices are delayed at least 15 minutes; real-time quotes are available from the Massive API.

### What is Ocular Therapeutix, Inc.?

Ocular Therapeutix Inc is a biotechnology company that specializes in therapies for diseases and conditions of the eye. The company uses its proprietary hydrogel platform technology to deliver therapeutic agents to the eye.

### What is the short interest in OCUL?

As of Oct 30, 2026, OCUL has 29M shares short and 10.1 days to cover.

### What exchange is OCUL listed on?

Ocular Therapeutix, Inc. (OCUL) trades on Nasdaq in USD, in the PHARMACEUTICAL PREPARATIONS industry.

## Live data

Prices here are 15-minute delayed. For real-time OCUL quotes and the full history behind this page, use the Massive API or MCP server:

- `GET https://api.massive.com/v3/snapshot?ticker.any_of=OCUL`

Requests need a Massive API key. API reference for agents: https://massive.com/docs/llms.txt. Connect an AI agent through the Massive MCP server: https://massive.com/docs/ai-tools.

## Related

- [Ocular Therapeutix, Inc. (OCUL) insider trading](https://massive.com/quote/ocul/insider-trading.md)
- [SEC 8-K events](https://massive.com/quote/sec-filings/8-k.md)
- [Markets overview](https://massive.com/quote/index.md)

Nothing here is investment advice. Data and content are provided for informational purposes under the Massive Terms of Service: https://massive.com/terms
